ICU Medical, Inc. (NASDAQ:ICUI) Director David C. Greenberg Sells 972 Shares of Stock

ICU Medical, Inc. (NASDAQ:ICUI) Director David C. Greenberg sold 972 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $158.11, for a total transaction of $153,682.92. Following the completion of the sale, the director now owns 5,037 shares of the company’s stock, valued at approximately $796,400.07. This trade represents a 16.18 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

ICU Medical Trading Up 1.3 %

Shares of ICUI stock opened at $159.75 on Thursday. The company has a market capitalization of $3.91 billion, a PE ratio of -34.96 and a beta of 0.66. ICU Medical, Inc. has a 52-week low of $83.26 and a 52-week high of $196.26. The business’s fifty day moving average is $175.61 and its 200 day moving average is $146.51. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Raymond James raised their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. KeyCorp raised their price target on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Jefferies Financial Group started coverage on ICU Medical in a report on Monday, October 14th. They set a “hold” rating and a $183.00 price objective for the company. Finally, Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, ICU Medical presently has a consensus rating of “Moderate Buy” and an average target price of $173.00.

Institutional Trading of ICU Medical

A number of large investors have recently modified their holdings of the business. Innealta Capital LLC bought a new position in shares of ICU Medical in the second quarter worth approximately $32,000. Hexagon Capital Partners LLC lifted its position in ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 122 shares during the last quarter. Allworth Financial LP grew its stake in ICU Medical by 100.0% in the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 100 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of ICU Medical by 46.4% in the 1st quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 173 shares during the last quarter. Finally, Venturi Wealth Management LLC increased its holdings in shares of ICU Medical by 1,510.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 302 shares during the last quarter. Institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.